FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078161086> ?p ?o ?g. }

• W2078161086 endingPage "e23428" @default.
• W2078161086 startingPage "e23428" @default.
• W2078161086 abstract "Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outcome in non-small cell lung cancer (NSCLC) patients treated with multimodal combination therapy. In a single-arm Phase II trial involving induction gemcitabine and carboplatin followed by concurrent paclitaxel, carboplatin and 74 Gy thoracic radiation in stage III NSCLC patients, plasma was drawn at baseline, post-induction, and post-concurrent therapy. The mean plasma Kyn/Trp ratio was used as a surrogate indicator of IDO activity. The 33 participants were distributed as follows: 15 females, 18 males; median age = 62; median overall survival (OS) = 22.4 (95% CI 19.3-25.1) months; median progression-free survival (PFS) = 11.5 (95% CI 6.7-16.3) months. The mean Kyn/Trp ratio at baseline (4.5 ± 2.8) was higher than that of healthy controls (2.9 ± 1.9, p = 0.03) and increased after induction therapy (5.2 ± 3.2, p = 0.08) and chemoradiation (5.8 ± 3.9, p = 0.01). The post-treatment Kyn/Trp ratio and radiologic responses were not significantly associated at any time point. No significant correlation was found between baseline Kyn/Trp ratios and OS (HR = 1.1, 95% CI 0.45-2.5) or PFS (HR = 0.74, 95% CI 0.30-1.82). A post-induction chemotherapy increase in IDO activity portended worse OS (HR = 0.43, 95% CI 0.19-0.95, p = 0.037) and PFS (HR = 0.47, 95% CI 0.22-1.0, p = 0.055). This observed increase in IDO transcription may be a means for tumors to evade immunosurveillance." @default.
• W2078161086 created "2016-06-24" @default.
• W2078161086 creator A5001557696 @default.
• W2078161086 creator A5010665082 @default.
• W2078161086 creator A5041062966 @default.
• W2078161086 creator A5046273815 @default.
• W2078161086 creator A5064826649 @default.
• W2078161086 creator A5090789911 @default.
• W2078161086 date "2013-03-01" @default.
• W2078161086 modified "2023-10-01" @default.
• W2078161086 title "Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer" @default.
• W2078161086 cites W1497557454 @default.
• W2078161086 cites W1553983160 @default.
• W2078161086 cites W16473764 @default.
• W2078161086 cites W1966481035 @default.
• W2078161086 cites W1967352051 @default.
• W2078161086 cites W1967404929 @default.
• W2078161086 cites W1968762811 @default.
• W2078161086 cites W1971360146 @default.
• W2078161086 cites W1973010974 @default.
• W2078161086 cites W1973251492 @default.
• W2078161086 cites W1977692898 @default.
• W2078161086 cites W1978992242 @default.
• W2078161086 cites W1981885178 @default.
• W2078161086 cites W1987204459 @default.
• W2078161086 cites W1992374256 @default.
• W2078161086 cites W2003635644 @default.
• W2078161086 cites W2004528113 @default.
• W2078161086 cites W2007489575 @default.
• W2078161086 cites W2007916488 @default.
• W2078161086 cites W2010378562 @default.
• W2078161086 cites W2013729937 @default.
• W2078161086 cites W2014545440 @default.
• W2078161086 cites W2021655024 @default.
• W2078161086 cites W2022369681 @default.
• W2078161086 cites W2029458048 @default.
• W2078161086 cites W2030410453 @default.
• W2078161086 cites W2030610701 @default.
• W2078161086 cites W2030923896 @default.
• W2078161086 cites W2043802040 @default.
• W2078161086 cites W2049552969 @default.
• W2078161086 cites W2052448890 @default.
• W2078161086 cites W2060411131 @default.
• W2078161086 cites W2061395079 @default.
• W2078161086 cites W2076232020 @default.
• W2078161086 cites W2078434983 @default.
• W2078161086 cites W2078703855 @default.
• W2078161086 cites W2079068389 @default.
• W2078161086 cites W2080287150 @default.
• W2078161086 cites W2083365094 @default.
• W2078161086 cites W2085324105 @default.
• W2078161086 cites W2089265092 @default.
• W2078161086 cites W2090043984 @default.
• W2078161086 cites W2090410108 @default.
• W2078161086 cites W2094644987 @default.
• W2078161086 cites W2110744505 @default.
• W2078161086 cites W2113846910 @default.
• W2078161086 cites W2117590636 @default.
• W2078161086 cites W2124533699 @default.
• W2078161086 cites W2127903252 @default.
• W2078161086 cites W2138820194 @default.
• W2078161086 cites W2138926114 @default.
• W2078161086 cites W2142874390 @default.
• W2078161086 cites W2146914242 @default.
• W2078161086 cites W2150633526 @default.
• W2078161086 cites W2154879572 @default.
• W2078161086 cites W2158734599 @default.
• W2078161086 cites W2166008430 @default.
• W2078161086 cites W2167897482 @default.
• W2078161086 cites W2171437874 @default.
• W2078161086 cites W2335128695 @default.
• W2078161086 cites W2626820697 @default.
• W2078161086 cites W4241827523 @default.
• W2078161086 cites W4253434423 @default.
• W2078161086 cites W4254765132 @default.
• W2078161086 doi "https://doi.org/10.4161/onci.23428" @default.
• W2078161086 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3661168" @default.
• W2078161086 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23802083" @default.
• W2078161086 hasPublicationYear "2013" @default.
• W2078161086 type Work @default.
• W2078161086 sameAs 2078161086 @default.
• W2078161086 citedByCount "72" @default.
• W2078161086 countsByYear W20781610862012 @default.
• W2078161086 countsByYear W20781610862014 @default.
• W2078161086 countsByYear W20781610862015 @default.
• W2078161086 countsByYear W20781610862016 @default.
• W2078161086 countsByYear W20781610862017 @default.
• W2078161086 countsByYear W20781610862018 @default.
• W2078161086 countsByYear W20781610862019 @default.
• W2078161086 countsByYear W20781610862020 @default.
• W2078161086 countsByYear W20781610862021 @default.
• W2078161086 countsByYear W20781610862022 @default.
• W2078161086 countsByYear W20781610862023 @default.
• W2078161086 crossrefType "journal-article" @default.
• W2078161086 hasAuthorship W2078161086A5001557696 @default.
• W2078161086 hasAuthorship W2078161086A5010665082 @default.
• W2078161086 hasAuthorship W2078161086A5041062966 @default.
• W2078161086 hasAuthorship W2078161086A5046273815 @default.

• next